GenMark Diagnostics Schedules First Quarter 2014 Financial Results Conference Call for May 6, 2014
April 24 2014 - 12:33PM
Business Wire
GenMark Diagnostics, Inc. (NASDAQ:GNMK) today announced that it
plans to release its first quarter earnings results after market
close on Tuesday, May 6, 2014. Management will hold a conference
call to review the Company's financial performance starting at 4:30
p.m. EDT on the same day. The conference call will be concurrently
webcast. The link to the webcast will be available on the GenMark
Diagnostics, Inc. website at www.genmarkdx.com under the investor
relations section and will be archived for future reference. To
listen to the conference call, please dial (877) 312-5847
(US/Canada) or (253) 237-1154 (International) and use the
conference ID number 35146653 approximately five minutes prior to
the start time.
About GenMark
GenMark Diagnostics is a leading provider of automated,
multiplex molecular diagnostic testing systems that detect and
measure DNA and RNA targets to diagnose disease and optimize
patient treatment. Utilizing GenMark's proprietary eSensor®
detection technology, GenMark's eSensor® XT-8 system is designed to
support a broad range of molecular diagnostic tests with a compact,
easy-to-use workstation and self-contained, disposable test
cartridges. GenMark currently markets four tests that are FDA
cleared for IVD use: Cystic Fibrosis Genotyping Test, Respiratory
Viral Panel, Thrombophilia Risk Test, and Warfarin Sensitivity
Test. A number of other tests, including HCV Genotyping, 2C19
Genotyping, and 3A4/3A5 Genotyping are available for research use
only. For more information, visit www.genmarkdx.com.
GenMark Diagnostics, Inc.Hany MassaranyPresident/Chief Executive
Officer760-448-4358
GenMark Diagnostics (NASDAQ:GNMK)
Historical Stock Chart
From Mar 2024 to Apr 2024
GenMark Diagnostics (NASDAQ:GNMK)
Historical Stock Chart
From Apr 2023 to Apr 2024